Shanghai Shyndec Pharmaceutical Co Ltd
SSE:600420
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.96
14.14
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shanghai Shyndec Pharmaceutical Co Ltd
Other Long-Term Assets
Shanghai Shyndec Pharmaceutical Co Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Shanghai Shyndec Pharmaceutical Co Ltd
SSE:600420
|
Other Long-Term Assets
ÂĄ189.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
30%
|
||
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Long-Term Assets
ÂĄ215.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
||
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Long-Term Assets
ÂĄ702.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
25%
|
CAGR 10-Years
33%
|
||
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Long-Term Assets
ÂĄ928.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
20%
|
||
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Long-Term Assets
ÂĄ84.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Shanghai Shyndec Pharmaceutical Co Ltd
Glance View
Shanghai Shyndec Pharmaceutical Co., Ltd. principally engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 11,937 full-time employees. The company went IPO on 2004-06-16. The firm's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The firm also offers topical preparations, such as gynecological suppositories and dermatology preparations.
See Also
What is Shanghai Shyndec Pharmaceutical Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
189.5m
CNY
Based on the financial report for Jun 30, 2024, Shanghai Shyndec Pharmaceutical Co Ltd's Other Long-Term Assets amounts to 189.5m CNY.
What is Shanghai Shyndec Pharmaceutical Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
30%
Over the last year, the Other Long-Term Assets growth was -30%. The average annual Other Long-Term Assets growth rates for Shanghai Shyndec Pharmaceutical Co Ltd have been -1% over the past three years , -4% over the past five years , and 30% over the past ten years .